Bulgak, MirkanDemirdal, Tuna2025-03-252025-03-2520252673-8112https://doi.org/10.3390/covid5020019https://hdl.handle.net/20.500.14365/5994This study aimed to evaluate the type, frequency, onset, and recovery duration of neurological symptoms caused by COVID-19, including newly emerging post-COVID-19 neurological findings, to contribute to improved prognosis and follow-up strategies. A total of 110 COVID-19 patients hospitalized with positive SARS-CoV-2 PCR tests (24 December 2021-10 March 2022) were prospectively assessed. Neurological symptoms during hospitalization and at 1, 3, and 6 months post-discharge were documented, with all findings confirmed by a neurologist. The time of symptom onset was recorded for each patient. Fatigue (75.5%) was the most common symptom, lasting 10.43 weeks on average, followed by myalgia (57.3%, 4.29 weeks) and headache (56.4%, 3.35 weeks). Forgetfulness persisted the longest (22.03 weeks). Headache and myalgia were more frequent in women, while symptoms like dizziness, insomnia, and nausea/vomiting were more common in patients aged <= 50. No significant differences in symptom duration were observed based on age or gender. Neurological symptoms, such as fatigue, headache, myalgia, and forgetfulness, were prevalent in both the acute and post-COVID-19 phases. The study underscores the importance of systematic neurological monitoring and the development of individualized follow-up strategies to manage long-term neurological effects and improve patient outcomes.eninfo:eu-repo/semantics/openAccessCovid-19Sars-Cov-2Post-Covid SyndromeNeurological SymptomsArticle10.3390/covid50200192-s2.0-85218680884